Oren Hershkovitz
Chief Executive Officer bei ENLIVEX THERAPEUTICS LTD.
Vermögen: 72 605 $ am 31.03.2024
Profil
Oren Hershkovitz is the Chief Executive Officer at Enlivex Therapeutics Ltd.
and also serves as the Director & General Manager at OPKO Biologics Ltd.
He holds a doctorate degree from Ben-Gurion University of the Negev.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.03.2023 | 19 157 ( 0,10% ) | 72 605 $ | 31.03.2024 |
Aktive Positionen von Oren Hershkovitz
| Unternehmen | Position | Beginn |
|---|---|---|
| ENLIVEX THERAPEUTICS LTD. | Chief Executive Officer | 16.11.2019 |
OPKO Biologics Ltd.
 OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | Director/Board Member | 01.09.2016 |
Ausbildung von Oren Hershkovitz
| Ben-Gurion University of the Negev | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ENLIVEX THERAPEUTICS LTD. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | Health Technology |
